The Use of Botulinum Toxin A in the Management of Trigeminal Neuralgia: a Systematic Literature Review.
botulinum A toxin
botulinum neurotoxin A
trigeminal nerve
trigeminal neuralgia
Journal
Journal of oral & maxillofacial research
ISSN: 2029-283X
Titre abrégé: J Oral Maxillofac Res
Pays: Lithuania
ID NLM: 101552108
Informations de publication
Date de publication:
Historique:
received:
13
05
2020
accepted:
29
06
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
8
8
2020
Statut:
epublish
Résumé
The purpose of this article is to systematically review the use, efficacy, differences between botulinum toxin type A doses and side effects of botulinum toxin type A therapy in patients with trigeminal neuralgia. The search for the performed reviews was done in PubMed and Cochrane library in English language from January 2010 up to February 2020. Inclusion criteria: full-text studies in English language, in which visual assessment scale (VAS) was present, in which patients with trigeminal neuralgia (TN) were participated and the comparison between botulinum toxin type A (BT-A) and saline was done. The review included 4 randomized, double-blind, placebo-controlled trials with 8 to 12 weeks follow-up to observe changes in VAS and in frequency of TN attacks, differences between dosages of BT-A in therapy and side effects. Mean VAS of BT-A group decreased by approximately 68% and of palcebo group decreased by approximately 21.6% after the therapy. Mean frequency of TN attacks in 3 studies of BT-A group decreased by 85%, while in palcebo by only 15.9%. Botulinum toxin type A injection therapy is a safe and effective method in management of trigeminal neuralgia. No differences between dosages of botulinum toxin type A were found. Maximum efficacy was noticed between 6 weeks and 3 months after the procedure. Side effects were mostly facial asymmetry after injection, headaches, haematoma, which disappeared in one week.
Identifiants
pubmed: 32760475
doi: 10.5037/jomr.2020.11202
pii: v11n2e2ht
pmc: PMC7393930
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e2Informations de copyright
Copyright © Rubis A, Juodzbalys G. Published in the JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 30 June 2020.
Références
Pain Med. 2013 Feb;14(2):276-86
pubmed: 23301515
Toxicon. 2020 Feb;175:64-68
pubmed: 32056697
Medicine (Baltimore). 2017 Sep;96(39):e8133
pubmed: 28953646
Int J Neurosci. 2016;126(4):348-53
pubmed: 26000810
Aesthet Surg J. 2013 Mar;33(1 Suppl):9S-12S
pubmed: 23515199
Eur J Neurol. 2019 Jun;26(6):831-849
pubmed: 30860637
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Jan;111(1):47-50
pubmed: 20674409
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar;109(3):e47-50
pubmed: 20219585
Med Clin (Barc). 2017 Jan 6;148(1):28-32
pubmed: 27743594
J Headache Pain. 2013 Nov 19;14:92
pubmed: 24251833
J Headache Pain. 2014 Sep 27;15:65
pubmed: 25263254
Toxins (Basel). 2020 Feb 11;12(2):
pubmed: 32053883
J Craniofac Surg. 2014 Jul;25(4):1393-6
pubmed: 24816027
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurosurg Clin N Am. 2017 Jul;28(3):429-438
pubmed: 28600016
Cephalalgia. 2012 Apr;32(6):443-50
pubmed: 22492424
Plast Reconstr Surg Glob Open. 2020 Jan 24;8(1):e2627
pubmed: 32095419
Expert Rev Neurother. 2017 Oct;17(10):1003-1011
pubmed: 28829200
Laryngoscope. 2014 Feb;124(2):413-7
pubmed: 23818108
J Headache Pain. 2014 Jun 22;15:43
pubmed: 24952600
Cephalalgia. 2018 May;38(6):1049-1056
pubmed: 28708009
Clin Neuropharmacol. 2013 Sep-Oct;36(5):146-50
pubmed: 24045604
Semin Neurol. 2016 Feb;36(1):29-33
pubmed: 26866493
Pain Res Treat. 2013;2013:831094
pubmed: 24194982
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jun;121(6):e148-53
pubmed: 27181448
Neurology. 2016 Jul 12;87(2):220-8
pubmed: 27306631
Headache. 2016 Jun;56(6):1035-9
pubmed: 26992044
Cephalalgia. 2012 Nov;32(15):1154-5; author reply 1156-7
pubmed: 22990690
J Headache Pain. 2013 Aug 21;14:72
pubmed: 23964790
Aesthet Surg J. 2019 Jun 21;39(Suppl_4):1-27
pubmed: 31226205